Despite all the global and local challenges; related and unrelated to the pandemic, 2021 has been a year of tremendous growth, progress and development at FORUS. We are excited about 2022 and look forward to fulfilling our mission by bringing innovative new medicines...

In recognition of this last day of September and the close of Blood Cancer Awareness Month, FORUS Therapeutics Inc. is pleased to announce that Health Canada has accepted for review the New Drug Submission (NDS) for once-weekly XPOVIO® (selinexor) in combination with...

FORUS Therapeutics is excited to introduce Kim Newhouse as the Senior Medical Manager. Recognized as a dedicated medical affairs business partner with a drive to deliver with excellence, Kim brings two decades of hematology/oncology launch experience in the Canadian...